Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
Date:11/12/2008

pectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

---------------------------------

(i) USA: HCUPnet; France, Agence technique de l'Information sur

l'Hospitalisation ; UK The Informatio
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Particle Sciences Expands Its Combination Product Capabilities
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor ... announced the set-up of an optical biopsy program at ... de Grenoble is now the first hospital in ... interventional pulmonology and urology patients an innovative platform for ... to the endomicroscopy technology developed by Mauna Kea Technologies. ...
(Date:3/31/2015)... 30, 2015 Research and Markets ( ... "Global Nuclear Imaging Market 2015-2019" report to their ... Imaging market to grow at a CAGR of 5.89 ... The report, Global Nuclear Imaging market 2015-2019, has been ... from industry experts. The report covers the Americas, and ...
(Date:3/31/2015)... DUBLIN , Mar. 27, 2015 Research and ... addition of the "Intraoperative Imaging Market by Type ... to 2019" report to their offering. ... at a CAGR of 3.5% from 2014 to 2019 ... future due to a number of forces that favor ...
Breaking Medicine Technology:Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 2Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 3Global Nuclear Imaging Market 2015-2019 with GE healthcare, Philips Healthcare & Siemens Healthcare Dominating 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2
... DALLAS, January 5, 2012 The " ... Billing & Coding) and Pharmaceutical (Clinical trial & Contract manufacturing) ... " analyzes and studies the major market drivers, restraints, ... and Rest of the world. Browse ...
...  The Musculoskeletal Transplant Foundation (MTF) has announced the release of ... kits. The new sizes--16cm x 20cm and 20cm x 20cm--are ... and their patients. This unique human dermal allograft is specifically ... It has been a year since MTF introduced its bi-lateral ...
Cached Medicine Technology:MarketsandMarkets: Global Healthcare BPO Market worth $330 Billion by 2016 2MarketsandMarkets: Global Healthcare BPO Market worth $330 Billion by 2016 3New, Larger, Bilateral Breast Graft Kits Announced by MTF 2
(Date:4/1/2015)... 2015 Amada Senior Care , premier ... recently opened a new office in Rocky Mount, NC – ... Lee Bissett decided to make the move to senior care ... over 20 years of experience in management and consulting. Their ... , When asked what makes Amada different from other ...
(Date:4/1/2015)... San Francisco based sustainable medical apparel manufacturer, ... Operation Smile, have launched a yearlong campaign ... RxOrganics is generously donating 5% of all purchases ... throughout 2015. RxOrganics has committed to an uncapped annual ... order placed online through the Rxmedical shop will have ...
(Date:4/1/2015)... 2015 Results are in for the ... featured 11 new homes from across the state exemplifying ... utilized innovative building techniques and new technology intended to ... Associates, Inc. (SWA) provided sustainability consulting services for 4 ... including the first- and third-place winners. , The Benker ...
(Date:4/1/2015)... Oak Brook, IL (PRWEB) April 01, 2015 ... unfortunately benefited greatly from climate change in recent years, ... will develop an allergic reaction if exposed to poison ... as outdoor enthusiasts and families prepare for summer adventures ... of an uncomfortable poison plant reaction is greater than ...
(Date:3/31/2015)... 2015 Bon Secours New York Health ... Schervier Nursing Care Center family last week. The Sisters ... in Yonkers which is scheduled to close later this ... of the Sisters of Charity of New York, the ... to place their Sisters at Schervier Nursing Care Center ...
Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2
... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ... ... LLP (ENTA) is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will ...
... which is the most common vascular complication after ... graft loss and devastating consequences. Surgical techniques are ... Despite improvements in surgical techniques, arterial reconstruction in ... With atraumatic microsurgical techniques, the reconstruction of HA ...
... of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought ... robust, non-invasive predictor of cardiovascular (CV) risk in patients ... the results of a multinational study presented today at ... Against Rheumatism in Rome, Italy. The presence of ...
... ... like driving, especially those parents who live in areas where public transportation is limited or ... group in Walnut Creek and San Francisco to cope with this and many other dilemmas. ... Walnut Creek, CA (PRWEB) ...
... after new rules took effect, study finds , THURSDAY, ... to doctors who administer outpatient chemotherapy drugs actually led ... finds a new study. , "This sort of dynamic ... economists often encounter this sort of thing," Joseph Newhouse, ...
... ... that it has added a brand new 2009 Cessna Grand Caravan to its fleet of modern ... (PRWEB) June 17, 2010 ... that it has added a brand new 2009 Cessna Grand Caravan to its fleet of modern ...
Cached Medicine News:Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs 2Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 2Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 3Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 4Health News:Medicare Cuts May Have Led Docs to Prescribe More Chemo 2Health News:Talon Air Adds A Brand New Cessna Grand Caravan Turbo Prop To Its Growing Private Jet Charter Fleet 2
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: